Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Opiophobia in Cancer Biology- Justified? - The Role of Perioperative Use of Opioids in Cancer Recurrence

Author(s): Mir W. Sekandarzad, Chris Doornebal and Markus W. Hollmann*

Volume 25, Issue 28, 2019

Page: [3020 - 3027] Pages: 8

DOI: 10.2174/1381612825666190703163329

Price: $65

Abstract

Opioids remain the standard of care in the provision of analgesia in the patient undergoing cancer surgery preoperatively.

The effects of opioids on tumor growth and metastasis have been discussed for many years. In recent years their use as part of the perioperative pain management bundle in the patients undergoing cancer surgery has been thought to promote cancer recurrence and metastasis.

This narrative review highlights earlier and more recent in vitro, in vivo and human retrospective studies that yield conflicting results as to the immune-modulatory effects of morphine on tumor biology. The article examines and explains the discrepancies with regards to the seemingly opposite results of morphine in the tumor milieu. The results of both, earlier studies that demonstrated procarcinogenic effects versus the data of more recent refined rodent studies that yielded neutral or even anti-carcinogenic effects are presented here.

Until the results of prospective randomized controlled trials are available to clarify this important question, it is currently not warranted to support opiophobia and opioids continue to constitute a pivotal role in the pain management of cancer patients.

Keywords: Cancer, tumor growth, metastasis, morphine, opiophobia, pain, in vitro studies.

« Previous Next »
[1]
Cancer Facts & Figures. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2018.html
[2]
Gach K, Wyrębska A, Fichna J, Janecka A. The role of morphine in regulation of cancer cell growth. Naunyn Schmiedebergs Arch Pharmacol 2011; 384(3): 221-30.
[http://dx.doi.org/10.1007/s00210-011-0672-4] [PMID: 21800094]
[3]
Sekandarzad MW, van Zundert AAJ, Lirk PB, Doornebal CW, Hollmann MW. Perioperative anesthesia care and tumor progression. Anesth Analg 2017; 124(5): 1697-708.
[http://dx.doi.org/10.1213/ANE.0000000000001652] [PMID: 27828796]
[4]
World Health Organization Cancer pain relief 1996. http://whqlibdoc.who.int/publications/9241544821.pdf
[5]
Afsharimani B, Cabot PJ, Parat MO. Morphine use in cancer surgery. Front Pharmacol 2011; 2: 46.
[http://dx.doi.org/10.3389/fphar.2011.00046] [PMID: 21852973]
[6]
Connolly C, Buggy DJ. Opioids and tumour metastasis: does the choice of the anesthetic-analgesic technique influence outcome after cancer surgery? Curr Opin Anaesthesiol 2016; 29(4): 468-74.
[http://dx.doi.org/10.1097/ACO.0000000000000360] [PMID: 27214644]
[7]
Page GG, Blakely WP, Ben-Eliyahu S. Evidence that postoperative pain is a mediator of the tumor-promoting effects of surgery in rats. Pain 2001; 90(1-2): 191-9.
[http://dx.doi.org/10.1016/S0304-3959(00)00403-6] [PMID: 11166986]
[8]
Ripamonti CI, Santini D, Maranzano E, Berti M, Roila F. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol 2012; 23(Suppl. 7): vii139-54.
[http://dx.doi.org/10.1093/annonc/mds233] [PMID: 22997447]
[9]
Magnon C, Hall SJ, Lin J, et al. Autonomic nerve development contributes to prostate cancer progression. Science 2013; 341(6142)1236361
[http://dx.doi.org/10.1126/science.1236361] [PMID: 23846904]
[10]
Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: Evidence-based recommendations from the EAPC. Lancet Oncol 2012; 13(2): e58-68.
[http://dx.doi.org/10.1016/S1470-2045(12)70040-2] [PMID: 22300860]
[11]
Afsharimani B, Doornebal CW, Cabot PJ, Hollmann MW, Parat MO. Comparison and analysis of the animal models used to study the effect of morphine on tumour growth and metastasis. Br J Pharmacol 2015; 172(2): 251-9.
[http://dx.doi.org/10.1111/bph.12589] [PMID: 24467261]
[12]
Zagon IS, McLaughlin PJ. Opioids and the apoptotic pathway in human cancer cells. Neuropeptides 2003; 37(2): 79-88.
[http://dx.doi.org/10.1016/S0143-4179(03)00007-6] [PMID: 12747939]
[13]
Page GG, Ben-Eliyahu S, Yirmiya R, Liebeskind JC. Morphine attenuates surgery-induced enhancement of metastatic colonization in rats. Pain 1993; 54(1): 21-8.
[http://dx.doi.org/10.1016/0304-3959(93)90095-7] [PMID: 8378099]
[14]
Page GG, McDonald JS, Ben-Eliyahu S. Pre-operative versus postoperative administration of morphine: Impact on the neuroendocrine, behavioural, and metastatic-enhancing effects of surgery. Br J Anaesth 1998; 81(2): 216-23.
[http://dx.doi.org/10.1093/bja/81.2.216] [PMID: 9813526]
[15]
Sasamura T, Nakamura S, Iida Y, et al. Morphine analgesia suppresses tumor growth and metastasis in a mouse model of cancer pain produced by orthotopic tumor inoculation. Eur J Pharmacol 2002; 441(3): 185-91.
[http://dx.doi.org/10.1016/S0014-2999(02)01450-4] [PMID: 12063091]
[16]
Tegeder I, Grösch S, Schmidtko A, et al. G protein-independent G1 cell cycle block and apoptosis with morphine in adenocarcinoma cells: Involvement of p53 phosphorylation. Cancer Res 2003; 63(8): 1846-52.
[PMID: 12702572]
[17]
Yeager MP, Colacchio TA. Effect of morphine on growth of metastatic colon cancer in vivo. Arch Surg 1991; 126(4): 454-6.
[http://dx.doi.org/10.1001/archsurg.1991.01410280056007] [PMID: 2009060]
[18]
Harimaya Y, Koizumi K, Andoh T, Nojima H, Kuraishi Y, Saiki I. Potential ability of morphine to inhibit the adhesion, invasion and metastasis of metastatic colon 26-L5 carcinoma cells. Cancer Lett 2002; 187(1-2): 121-7.
[http://dx.doi.org/10.1016/S0304-3835(02)00360-9] [PMID: 12359359]
[19]
Koodie L, Ramakrishnan S, Roy S. Morphine suppresses tumor angiogenesis through a HIF-1alpha/p38MAPK pathway. Am J Pathol 2010; 177(2): 984-97.
[http://dx.doi.org/10.2353/ajpath.2010.090621] [PMID: 20616349]
[20]
Tegeder I, Geisslinger G. Opioids as modulators of cell death and survival--unraveling mechanisms and revealing new indications. Pharmacol Rev 2004; 56(3): 351-69.
[http://dx.doi.org/10.1124/pr.56.3.2] [PMID: 15317908]
[21]
Maneckjee R, Biswas R, Vonderhaar BK. Binding of opioids to human MCF-7 breast cancer cells and their effects on growth. Cancer Res 1990; 50(8): 2234-8.
[PMID: 2156613]
[22]
Ash SA, Buggy DJ. Does regional anaesthesia and analgesia or opioid analgesia influence recurrence after primary cancer surgery? An update of available evidence. Best Pract Res Clin Anaesthesiol 2013; 27(4): 441-56.
[http://dx.doi.org/10.1016/j.bpa.2013.10.005] [PMID: 24267550]
[23]
Aich A, Gupta P, Gupta K. Could perioperative opioid use increase the risk of cancer progression and metastases? Int Anesthesiol Clin 2016; 54(4): e1-e16.
[http://dx.doi.org/10.1097/AIA.0000000000000112] [PMID: 27602710]
[24]
Kuo CK, Hanioka N, Hoshikawa Y, Oguri K, Yoshimura H. Species difference of site-selective glucuronidation of morphine. J Pharmacobiodyn 1991; 14(4): 187-93.
[http://dx.doi.org/10.1248/bpb1978.14.187] [PMID: 1941499]
[25]
Maneckjee R, Minna JD. Opioids induce while nicotine suppresses apoptosis in human lung cancer cells. Cell Growth Differ 1994; 5(10): 1033-40.
[PMID: 7848904]
[26]
Hsiao PN, Chang MC, Cheng WF, et al. Morphine induces apoptosis of human endothelial cells through nitric oxide and reactive oxygen species pathways. Toxicology 2009; 256(1-2): 83-91.
[http://dx.doi.org/10.1016/j.tox.2008.11.015] [PMID: 19070643]
[27]
Hatsukari I, Hitosugi N, Matsumoto I, Nagasaka H, Sakagami H. Induction of early apoptosis marker by morphine in human lung and breast carcinoma cell lines. Anticancer Res 2003; 23(3B): 2413-7.
[PMID: 12894522]
[28]
Hatsukari I, Hitosugi N, Ohno R, et al. Induction of apoptosis by morphine in human tumor cell lines in vitro. Anticancer Res 2007; 27(2): 857-64.
[PMID: 17465212]
[29]
Snyder GL, Greenberg S. Effect of anaesthetic technique and other perioperative factors on cancer recurrence. Br J Anaesth 2010; 105(2): 106-15.
[http://dx.doi.org/10.1093/bja/aeq164] [PMID: 20627881]
[30]
Aherne GW, Piall EM, Twycross RG. Serum morphine concentration after oral administration of diamorphine hydrochloride and morphine sulphate. Br J Clin Pharmacol 1979; 8(6): 577-80.
[http://dx.doi.org/10.1111/j.1365-2125.1979.tb01047.x] [PMID: 533579]
[31]
Koodie L, Yuan H, Pumper JA, et al. Morphine inhibits migration of tumor-infiltrating leukocytes and suppresses angiogenesis associated with tumor growth in mice. Am J Pathol 2014; 184(4): 1073-84.
[http://dx.doi.org/10.1016/j.ajpath.2013.12.019] [PMID: 24495739]
[32]
Afsharimani B, Cabot PJ, Parat MO. Effect of lysine antifibrinolytics and cyclooxygenase inhibitors on the proteolytic profile of breast cancer cells interacting with macrophages or endothelial cells. Br J Anaesth 2014; 113(Suppl. 1): i22-31.
[http://dx.doi.org/10.1093/bja/aet468] [PMID: 24418973]
[33]
Khabbazi S, Goumon Y, Parat MO. Morphine modulates interleukin-4- or breast cancer cell-induced pro-metastatic activation of macrophages. Sci Rep 2015; 5: 11389.
[http://dx.doi.org/10.1038/srep11389] [PMID: 26078009]
[34]
Eckhardt BL, Francis PA, Parker BS, Anderson RL. Strategies for the discovery and development of therapies for metastatic breast cancer. Nat Rev Drug Discov 2012; 11(6): 479-97.
[http://dx.doi.org/10.1038/nrd2372] [PMID: 22653217]
[35]
Afsharimani B, Baran J, Watanabe S, Lindner D, Cabot PJ, Parat MO. Morphine and breast tumor metastasis: The role of matrix-degrading enzymes. Clin Exp Metastasis 2014; 31(2): 149-58.
[http://dx.doi.org/10.1007/s10585-013-9616-3] [PMID: 24072419]
[36]
Li J, Yang F, Wei F, Ren X. The role of toll-like receptor 4 in tumor microenvironment. Oncotarget 2017; 8(39): 66656-67.
[http://dx.doi.org/10.18632/oncotarget.19105] [PMID: 29029545]
[37]
Gach K, Szemraj J, Wyrębska A, Janecka A. The influence of opioids on matrix metalloproteinase-2 and -9 secretion and mRNA levels in MCF-7 breast cancer cell line. Mol Biol Rep 2011; 38(2): 1231-6.
[http://dx.doi.org/10.1007/s11033-010-0222-z] [PMID: 20563853]
[38]
Shariftabrizi A, Nifli AP, Ansari M, et al. Matrix metalloproteinase 2 secretion in WEHI 164 fibrosarcoma cells is nitric oxide-related and modified by morphine. Eur J Pharmacol 2006; 530(1-2): 33-9.
[http://dx.doi.org/10.1016/j.ejphar.2005.11.043] [PMID: 16386243]
[39]
Doornebal CW, Vrijland K, Hau CS, et al. Morphine does not facilitate breast cancer progression in two preclinical mouse models for human invasive lobular and HER2+ breast cancer. Pain 2015; 156(8): 1424-32.
[http://dx.doi.org/10.1097/j.pain.0000000000000136] [PMID: 25734987]
[40]
Kim JY, Ahn HJ, Kim JK, Kim J, Lee SH, Chae HB. Morphine suppresses lung cancer cell proliferation through the interaction with opioid growth factor receptor: An in vitro and human lung tissue study. Anesth Analg 2016; 123(6): 1429-36.
[http://dx.doi.org/10.1213/ANE.0000000000001293] [PMID: 27167686]
[41]
Kurosawa S. Anesthesia in patients with cancer disorders. Curr Opin Anaesthesiol 2012; 25(3): 376-84.
[http://dx.doi.org/10.1097/ACO.0b013e328352b4a8] [PMID: 22450698]
[42]
Lennon FE, Moss J, Singleton PA. The μ-opioid receptor in cancer progression: Is there a direct effect? Anesthesiology 2012; 116(4): 940-5.
[http://dx.doi.org/10.1097/ALN.0b013e31824b9512] [PMID: 22357347]
[43]
Kurosawa S, Kato M. Anesthetics, immune cells, and immune responses. J Anesth 2008; 22(3): 263-77.
[http://dx.doi.org/10.1007/s00540-008-0626-2] [PMID: 18685933]
[44]
Sacerdote P. Opioids and the immune system. Palliat Med 2006; 20(Suppl. 1): s9-s15.
[PMID: 16764216]
[45]
Cao LH, Li HT, Lin WQ, et al. Morphine, a potential antagonist of cisplatin cytotoxicity, inhibits cisplatin-induced apoptosis and suppression of tumor growth in nasopharyngeal carcinoma xenografts. Sci Rep 2016; 6: 18706.
[http://dx.doi.org/10.1038/srep18706] [PMID: 26729257]
[46]
Al-Hashimi M, Scott SW, Thompson JP, Lambert DG. Opioids and immune modulation: More questions than answers. Br J Anaesth 2013; 111(1): 80-8.
[http://dx.doi.org/10.1093/bja/aet153] [PMID: 23794649]
[47]
Afsharimani B, Cabot P, Parat MO. Morphine and tumor growth and metastasis. Cancer Metastasis Rev 2011; 30(2): 225-38.
[http://dx.doi.org/10.1007/s10555-011-9285-0] [PMID: 21267766]
[48]
Lennon FE, Mirzapoiazova T, Mambetsariev B, Salgia R, Moss J, Singleton PA. Overexpression of the μ-opioid receptor in human non-small cell lung cancer promotes Akt and mTOR activation, tumor growth, and metastasis. Anesthesiology 2012; 116(4): 857-67.
[http://dx.doi.org/10.1097/ALN.0b013e31824babe2] [PMID: 22343475]
[49]
Lennon FE, Mirzapoiazova T, Mambetsariev B, et al. The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer. PLoS One 2014; 9(3)e91577
[http://dx.doi.org/10.1371/journal.pone.0091577] [PMID: 24662916]
[50]
Yao YS, Yao RY, Zhuang LK, et al. MOR1 expression in gastric cancer: A biomarker associated with poor outcome. Clin Transl Sci 2015; 8(2): 137-42.
[http://dx.doi.org/10.1111/cts.12246] [PMID: 25441763]
[51]
Zylla D, Gourley BL, Vang D, et al. Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer. Cancer 2013; 119(23): 4103-10.
[http://dx.doi.org/10.1002/cncr.28345] [PMID: 24104703]
[52]
Nylund G, Pettersson A, Bengtsson C, Khorram-Manesh A, Nordgren S, Delbro DS. Functional expression of mu-opioid receptors in the human colon cancer cell line, HT-29, and their localization in human colon. Dig Dis Sci 2008; 53(2): 461-6.
[http://dx.doi.org/10.1007/s10620-007-9897-y] [PMID: 17680363]
[53]
Fujioka N, Nguyen J, Chen C, et al. Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer. Anesth Analg 2011; 113(6): 1353-64.
[http://dx.doi.org/10.1213/ANE.0b013e318232b35a] [PMID: 22003224]
[54]
Mathew B, Lennon FE, Siegler J, et al. The novel role of the mu opioid receptor in lung cancer progression: A laboratory investigation. Anesth Analg 2011; 112(3): 558-67.
[http://dx.doi.org/10.1213/ANE.0b013e31820568af] [PMID: 21156980]
[55]
Ecimovic P, Murray D, Doran P, McDonald J, Lambert DG, Buggy DJ. Direct effect of morphine on breast cancer cell function in vitro: Role of the NET1 gene. Br J Anaesth 2011; 107(6): 916-23.
[http://dx.doi.org/10.1093/bja/aer259] [PMID: 21857017]
[56]
Leo S, Nuydens R, Meert TF. Opioid-induced proliferation of vascular endothelial cells. J Pain Res 2009; 2: 59-66.
[PMID: 21197294]
[57]
Singleton PA, Lingen MW, Fekete MJ, Garcia JG, Moss J. Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: Role of receptor transactivation. Microvasc Res 2006; 72(1-2): 3-11.
[http://dx.doi.org/10.1016/j.mvr.2006.04.004] [PMID: 16820176]
[58]
Gupta K, Kshirsagar S, Chang L, et al. Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res 2002; 62(15): 4491-8.
[PMID: 12154060]
[59]
Chen C, Farooqui M, Gupta K. Morphine stimulates vascular endothelial growth factor-like signaling in mouse retinal endothelial cells. Curr Neurovasc Res 2006; 3(3): 171-80.
[http://dx.doi.org/10.2174/156720206778018767] [PMID: 16918381]
[60]
Gach K, Szemraj J, Fichna J, Piestrzeniewicz M, Delbro DS, Janecka A. The influence of opioids on urokinase plasminogen activator on protein and mRNA level in MCF-7 breast cancer cell line. Chem Biol Drug Des 2009; 74(4): 390-6.
[http://dx.doi.org/10.1111/j.1747-0285.2009.00875.x] [PMID: 19691469]
[61]
Singleton PA, Moss J. Effect of perioperative opioids on cancer recurrence: A hypothesis. Future Oncol 2010; 6(8): 1237-42.
[http://dx.doi.org/10.2217/fon.10.99] [PMID: 20799870]
[62]
Singleton PA, Moreno-Vinasco L, Sammani S, Wanderling SL, Moss J, Garcia JG. Attenuation of vascular permeability by methylnaltrexone: Role of mOP-R and S1P3 transactivation. Am J Respir Cell Mol Biol 2007; 37(2): 222-31.
[http://dx.doi.org/10.1165/rcmb.2006-0327OC] [PMID: 17395891]
[63]
Singleton PA, Mirzapoiazova T, Hasina R, Salgia R, Moss J. Increased μ-opioid receptor expression in metastatic lung cancer. Br J Anaesth 2014; 113(Suppl. 1): i103-8.
[http://dx.doi.org/10.1093/bja/aeu165] [PMID: 24920011]
[64]
Cata JP, Keerty V, Keerty D, et al. A retrospective analysis of the effect of intraoperative opioid dose on cancer recurrence after non-small cell lung cancer resection. Cancer Med 2014; 3(4): 900-8.
[http://dx.doi.org/10.1002/cam4.236] [PMID: 24692226]
[65]
Maher DP, Wong W, White PF, et al. Association of increased postoperative opioid administration with non-small-cell lung cancer recurrence: A retrospective analysis. Br J Anaesth 2014; 113(Suppl. 1): i88-94.
[http://dx.doi.org/10.1093/bja/aeu192] [PMID: 25009195]
[66]
Zylla D, Kuskowski MA, Gupta K, Gupta P. Association of opioid requirement and cancer pain with survival in advanced non-small cell lung cancer. Br J Anaesth 2014; 113(Suppl. 1): i109-16.
[http://dx.doi.org/10.1093/bja/aeu351] [PMID: 25303989]
[67]
Wang K, Qu X, Wang Y, Shen H, Liu Q, Du J. Effect of mu agonists on long-term survival and recurrence in nonsmall cell lung cancer patients. Medicine (Baltimore) 2015; 94(33)e1333
[http://dx.doi.org/10.1097/MD.0000000000001333] [PMID: 26287418]
[68]
Domcke S, Sinha R, Levine DA, Sander C, Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun 2013; 4: 2126.
[http://dx.doi.org/10.1038/ncomms3126] [PMID: 23839242]
[69]
Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: A looking glass for cancer? Nat Rev Cancer 2012; 12(5): 323-34.
[http://dx.doi.org/10.1038/nrc3261] [PMID: 22513401]
[70]
Jonkers J, Derksen PW. Modeling metastatic breast cancer in mice. J Mammary Gland Biol Neoplasia 2007; 12(2-3): 191-203.
[http://dx.doi.org/10.1007/s10911-007-9050-8] [PMID: 17587153]
[71]
Thompson EW, Haviv I. The social aspects of EMT-MET plasticity. Nat Med 2011; 17(9): 1048-9.
[http://dx.doi.org/10.1038/nm.2437] [PMID: 21900919]
[72]
Willimsky G, Czéh M, Loddenkemper C, et al. Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. J Exp Med 2008; 205(7): 1687-700.
[http://dx.doi.org/10.1084/jem.20072016] [PMID: 18573907]
[73]
Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: Integrating immunity’s roles in cancer suppression and promotion. Science 2011; 331(6024): 1565-70.
[http://dx.doi.org/10.1126/science.1203486] [PMID: 21436444]
[74]
Liao SJ, Zhou YH, Yuan Y, et al. Triggering of Toll-like receptor 4 on metastatic breast cancer cells promotes αvβ3-mediated adhesion and invasive migration. Breast Cancer Res Treat 2012; 133(3): 853-63.
[http://dx.doi.org/10.1007/s10549-011-1844-0] [PMID: 22042369]
[75]
Wang X, Loram LC, Ramos K, et al. Morphine activates neuroinflammation in a manner parallel to endotoxin. Proc Natl Acad Sci USA 2012; 109(16): 6325-30.
[http://dx.doi.org/10.1073/pnas.1200130109] [PMID: 22474354]
[76]
Hutchinson MR, Zhang Y, Shridhar M, et al. Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav Immun 2010; 24(1): 83-95.
[http://dx.doi.org/10.1016/j.bbi.2009.08.004] [PMID: 19679181]
[77]
Matzner P, Sorski L, Shaashua L, et al. Perioperative treatment with the new synthetic TLR-4 agonist GLA-SE reduces cancer metastasis without adverse effects. Int J Cancer 2016; 138(7): 1754-64.
[PMID: 26453448]
[78]
Forget P, Collet V, Lavand’homme P, De Kock M. Does analgesia and condition influence immunity after surgery? Effects of fentanyl, ketamine and clonidine on natural killer activity at different ages. Eur J Anaesthesiol 2010; 27(3): 233-40.
[http://dx.doi.org/10.1097/EJA.0b013e32832d540e] [PMID: 19487949]
[79]
Yeager MP, Procopio MA, DeLeo JA, Arruda JL, Hildebrandt L, Howell AL. Intravenous fentanyl increases natural killer cell cytotoxicity and circulating CD16(+) lymphocytes in humans. Anesth Analg 2002; 94(1): 94-9.
[PMID: 11772808]
[80]
Liang X, Liu R, Chen C, Ji F, Li T. Opioid System modulates the immune function: A review. Transl Perioper Pain Med 2016; 1(1): 5-13.
[PMID: 26985446]
[81]
Meserve JR, Kaye AD, Prabhakar A, Urman RD. The role of analgesics in cancer propagation. Best Pract Res Clin Anaesthesiol 2014; 28(2): 139-51.
[http://dx.doi.org/10.1016/j.bpa.2014.04.004] [PMID: 24993435]
[82]
Franchi S, Panerai AE, Sacerdote P. Buprenorphine ameliorates the effect of surgery on hypothalamus-pituitary-adrenal axis, natural killer cell activity and metastatic colonization in rats in comparison with morphine or fentanyl treatment. Brain Behav Immun 2007; 21(6): 767-74.
[http://dx.doi.org/10.1016/j.bbi.2007.01.001] [PMID: 17291715]
[83]
Husmann K, Arlt MJ, Jirkof P, Arras M, Born W, Fuchs B. Primary tumour growth in an orthotopic osteosarcoma mouse model is not influenced by analgesic treatment with buprenorphine and meloxicam. Lab Anim 2015; 49(4): 284-93.
[http://dx.doi.org/10.1177/0023677215570989] [PMID: 25650386]
[84]
Sacerdote P, Bianchi M, Gaspani L, et al. The effects of tramadol and morphine on immune responses and pain after surgery in cancer patients. Anesth Analg 2000; 90(6): 1411-4.
[http://dx.doi.org/10.1097/00000539-200006000-00028] [PMID: 10825330]
[85]
Friesen C, Roscher M, Hormann I, et al. Cell death sensitization of leukemia cells by opioid receptor activation. Oncotarget 2013; 4(5): 677-90.
[http://dx.doi.org/10.18632/oncotarget.952] [PMID: 23633472]
[86]
Friesen C, Hormann I, Roscher M, et al. Opioid receptor activation triggering downregulation of cAMP improves effectiveness of anti-cancer drugs in treatment of glioblastoma. Cell Cycle 2014; 13(10): 1560-70.
[http://dx.doi.org/10.4161/cc.28493] [PMID: 24626197]
[87]
Hooijmans CR, Geessink FJ, Ritskes-Hoitinga M, Scheffer GJ. A systematic review and meta-analysis of the ability of analgesic drugs to reduce metastasis in experimental cancer models. Pain 2015; 156(10): 1835-44.
[http://dx.doi.org/10.1097/j.pain.0000000000000296] [PMID: 26181303]
[88]
Sekandarzad MW, van Zundert AAJ, Doornebal CW, Hollmann MW. Regional anesthesia and analgesia in cancer care: Is it time to break the bad news? Curr Opin Anaesthesiol 2017; 30(5): 606-12.
[http://dx.doi.org/10.1097/ACO.0000000000000492] [PMID: 28700368]
[89]
Boland JW, McWilliams K, Ahmedzai SH, Pockley AG. Effects of opioids on immunologic parameters that are relevant to anti-tumour immune potential in patients with cancer: A systematic literature review. Br J Cancer 2014; 111(5): 866-73.
[http://dx.doi.org/10.1038/bjc.2014.384] [PMID: 25025960]
[90]
Janku F, Johnson LK, Karp DD, Atkins JT, Singleton PA, Moss J. Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer. Ann Oncol 2016; 27(11): 2032-8.
[http://dx.doi.org/10.1093/annonc/mdw317] [PMID: 27573565]
[91]
Cronin-Fenton DP, Heide-Jørgensen U, Ahern TP, et al. Opioids and breast cancer recurrence: A Danish population-based cohort study. Cancer 2015; 121(19): 3507-14.
[http://dx.doi.org/10.1002/cncr.29532] [PMID: 26207518]
[92]
Cronin-Fenton D, Lash TL, Ahern TP, et al. Concurrent new drug prescriptions and prognosis of early breast cancer: Studies using the Danish Breast Cancer Group clinical database. Acta Oncol 2018; 57(1): 120-8.
[http://dx.doi.org/10.1080/0284186X.2017.1407040] [PMID: 29202630]
[93]
Boland JW, Ziegler L, Boland EG, McDermid K, Bennett MI. Is regular systemic opioid analgesia associated with shorter survival in adult patients with cancer? A systematic literature review. Pain 2015; 156(11): 2152-63.
[http://dx.doi.org/10.1097/j.pain.0000000000000306] [PMID: 26207652]

Rights & Permissions Print Cite
Article Metrics
28
4
2
1
© 2024 Bentham Science Publishers | Privacy Policy